N-cyanoacetylurethane | 68168-42-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-cyanoacetylurethane
• 英文别名: Ethyl N-(cyanocarbonyl)carbamate；ethyl N-carbonocyanidoylcarbamate
• CAS: 68168-42-3
• 化学式: C₅H₆N₂O₃
• 分子量: 142.114
• InChiKey: DSFRCEAWEBDIOE-UHFFFAOYSA-N

物化性质

• 密度：
  1.247±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4-amino-2,6-dichlorophenoxy)-4-isopropyl-2-methylpyridazin-3(2H)-one 、 N-cyanoacetylurethane 在 盐酸 、 sodium nitrate 、 溶剂黄146 、 sodium acetate 作用下， 以 水 为溶剂， 反应 1.0h， 以95%的产率得到(2-cyano-2-{[3,5-dichloro-4-(5-isopropyl-1-methyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]hydrazono}acetyl)carbamic acid ethyl ester
  参考文献：
  名称：

  Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

  摘要：

  The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor beta (THR-beta) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor alpha (THR-alpha). A pyridazinone series has been identified that is significantly more THR-beta selective than earlier analogues. Optimization of this series by the addition of a cyanoazauracil substituent improved both the potency and selectivity and led to MGL-3196 (53), which is 28-fold selective for THR-beta over THR-alpha in a functional assay. Compound 53 showed outstanding safety in a rat heart model and was efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. In reported studies in healthy volunteers, 53 exhibited an excellent safety profile and decreased LDL cholesterol (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.

  DOI：

  10.1021/jm4019299
• 作为试剂：
  描述：

  6-（4-氨基-2,6-二氯苯氧基）-4-异丙基哒嗪-3（2H）-酮 、 N-cyanoacetylurethane 在 N-cyanoacetylurethane 作用下， 以76的产率得到(Z)-ethyl (2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazono)acetyl)carbamate
  参考文献：
  名称：

  J. Med. Chem. 2014, 57, 3912-3923

  摘要：

  DOI：

文献信息

• THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF
  申请人：Terns, Inc.

  公开号：US20200190064A1

  公开（公告）日：2020-06-18

  The present invention discloses a compound represented by the following Formula (I) and a pharmaceutically acceptable salt thereof. The compound improves the THRα selectivity while maintaining good THRβ agonistic activity, thereby improving properties of the finished drug.

  本发明公开了一种由以下化学式（I）表示的化合物及其药用可接受的盐。该化合物在保持良好的THRβ激动活性的同时提高了对THRα的选择性，从而改善了最终药物的性能。
• METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF
  申请人：Madrigal Pharmaceuticals, Inc.

  公开号：US20160243126A1

  公开（公告）日：2016-08-25

  The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TRβ mutation.

  该披露描述了合成吡啶并酮化合物作为甲状腺激素类似物及其前药的方法。根据该披露的首选方法可允许大规模制备高纯度的吡啶并酮化合物。在某些实施例中，根据该披露的首选方法还可允许比以前用于制备此类化合物的方法更好地制备吡啶并酮化合物。此外，还披露了一种吡啶并酮化合物的形态形式。进一步披露了一种治疗至少具有一种TRβ突变的主体的甲状腺激素抵抗的方法。